Otsuka's delamanid meets TB endpoint

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) said twice-daily delamanid in combination with standard background regimen for multidrug-resistant tuberculosis met the primary endpoint vs. background therapy alone in a Phase IIb trial. The endpoint measured the proportion of patients with sputum-culture conversion in liquid broth medium at two months. The double-blind, international trial enrolled 481 patients aged 18-64 with suspected multi-drug resistant TB infection. ...